LifeVantage Corporation — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2022; filed February 2, 2023. LifeVantage sells nutrigenomics, dietary supplements, personal care and related products through a direct-selling network of independent distributors and customers.
Financial results
| Metric | Q2 FY2023 | Q2 FY2022 | Six months FY2023 | Six months FY2022 |
|---|---|---|---|---|
| Revenue | $53.7 million | $52.2 million | $105.4 million | $105.4 million |
| Gross margin | 78.1% | 81.5% | 79.4% | 81.9% |
| Operating income (loss) | $(1.2) million | $(0.4) million | $0.1 million | $4.3 million |
| Net income (loss) | $(1.1) million | $0.1 million | $(0.4) million | $3.4 million |
| Diluted EPS | $(0.08) | $0.01 | $(0.04) | $0.25 |
- Margins and expenses: Gross margin declined, primarily from higher shipping costs and changes in geographic and product mix. Six-month commissions and incentives fell to 44.9% of revenue from 47.0%, while SG&A rose to 34.4% from 30.8%, reflecting higher event and travel costs, compensation, and professional services.
- Cash flow: Six-month operating cash flow was $(0.4) million, versus $4.5 million provided a year earlier. Investing used $1.6 million, primarily for property and equipment; financing used $0.7 million, including $0.8 million in dividends.
- Liquidity and balance sheet: Cash was $17.4 million at December 31, down from $20.2 million at June 30, 2022. Working capital was $21.0 million. Inventory increased to $20.4 million from $16.5 million. Total liabilities were $35.9 million, including $14.3 million of lease liabilities.
- Debt: The term loan had been repaid in full by fiscal 2020. The amended credit facility provides a revolving line of up to $5.0 million, maturing March 2024; the filing does not provide a clear amount drawn at quarter-end. The company reported compliance with covenants.
Material changes and management commentary
- Quarterly revenue increased 2.8%, but six-month revenue was essentially flat. Americas revenue rose 14.4% in the quarter; Asia/Pacific & Europe fell 20.2%. In the six-month period, U.S. revenue grew 8.1%, while Japan declined 21.7% and Australia/New Zealand declined 40.3%.
- Foreign exchange reduced revenue by approximately $2.4 million in the quarter and $5.0 million for six months. Japan revenue declined 8.3% and 2.0% on a constant-currency basis for those periods, respectively.
- Active accounts fell 8.6% year over year to 149,000, including 60,000 active distributors (down 3.2%) and 89,000 active customers (down 11.9%). Management attributed Americas revenue growth partly to higher average revenue per account and sales of TrueScience Liquid Collagen.
- Management expects cash and operating cash flow to cover requirements for at least the next 12 months. It expects continued product expansion in the second half of fiscal 2023, but provided no specific revenue or earnings guidance in the filing.
Risks, contingencies and unusual items
- Management cited distributor recruitment and retention, product acceptance, dependence on key products and third-party manufacturers, supply-chain and inventory management, foreign exchange, regulation, and COVID-related disruption among business risks. Japan’s in-person introductory-packet requirement continued to constrain distributor enrollment.
- The company recorded $0.4 million of SG&A expense related to abandoning Hong Kong and Singapore showroom right-of-use assets and changes to operations in those markets.
- The Smith class action was dismissed with prejudice on December 15, 2022, concluding the litigation. Management reported no probable loss contingencies requiring accrual or disclosure.
- An amendment to the credit facility effective September 30, 2022 revised the fixed-charge coverage calculation and permitted dividends of up to $500,000 per quarter through September 30, 2023. Quarterly dividends declared were $0.03 per share.
- The company reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter.
Investor verification points
- Track active customer and distributor counts, especially in Asia/Pacific & Europe, and whether product launches offset account attrition.
- Assess the persistence of shipping, product-mix and SG&A pressures and the impact on gross and operating margins.
- Monitor inventory growth, operating cash generation, and the actual amount drawn under the revolving credit facility.
- Verify performance against credit covenants, dividend limits and the company’s stated 12-month liquidity assessment.